CTLA-4 regulates cell cycle progression during a primary immune response. - Wikidata - wikimedia - TriplyDB

CTLA-4 regulates cell cycle progression during a primary immune response.

CTLA-4 regulates cell cycle progression during a primary immune response.

http://www.wikidata.org/entity/Q34520577

about

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Regulatory T cell: a protection for tumour cells CTLA-4 blockade in tumor models: an overview of preclinical and translational research Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease Immunotherapeutic strategies in autoimmune uveitis The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression.Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.CTLA-4: new insights into its biological function and use in tumor immunotherapy.Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.Current evidence on the cytotoxic T-lymphocyte antigen 4 + 49G > A polymorphism and digestive system cancer risks: a meta-analysis involving 11,923 subjects.Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuv The role of the CTLA4 blockade in the treatment of malignant melanoma.Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis.CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.Modulation of CTLA-4 and GITR for cancer immunotherapy.Immune regulatory antibodies: are they the next advance?Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review.Emerging immune checkpoints for cancer therapy.Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis.CTLA-4 +49 A/G and -318 C/T polymorphisms and susceptibility to multiple sclerosis: a meta-analysis.Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia.The CTLA-4 and MCP-1 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis.Association between the CTLA-4 +49 A/G polymorphism and susceptibility to rheumatoid arthritis: a meta-analysis.CTLA-4 polymorphisms and susceptibility to Behcet's disease: a meta-analysis The CTLA-4 +49 A/G and -318 C/T polymorphisms and susceptibility to asthma: a meta-analysis CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients

P2860

Q24679736-DF740680-54A5-496B-9918-547DC5014702 Q26991447-8346274B-8C11-4468-8D1F-9E9DDC16E414 Q26992295-C263332D-950C-49DA-BCC9-CE029E1F89BB Q34264559-63C9C12D-EF75-47F2-98AD-529006C79E6A Q34274950-0DB16BF9-06D8-4B7D-97C9-7E98E9C4DC61 Q34417483-C1024496-586F-45E8-B3BA-590B86E08F38 Q34437911-69DCA723-06BD-442B-AAE3-FEF8E1B6D366 Q34657638-05AC1096-22FE-4B1D-B0E8-28ABDA5CB2F5 Q34711491-B52CBD32-4535-4979-BBE2-0B6D96EADF7A Q34925487-B28AE051-1BB9-4288-AF13-7ECDA9BF7E12 Q36046801-E071FED3-4FD3-4648-80E1-42AED98BA0D1 Q36080721-51FD42EB-C7DB-4238-8EB6-6ED11B203EBA Q36251914-CD9DD2D1-A562-42E1-B2E1-4D74C0188B40 Q36286133-1D82ECA9-9485-430E-92B7-CA1E815BF0C1 Q36744405-6F272226-2E3A-435A-9D74-A69DE095F310 Q37008621-280723EB-3B84-4B22-8095-B83AB8A8051A Q37014061-7DAF1C26-549B-46D2-8E26-1EB5839FDBAE Q37018839-FDE0151E-467D-400E-AE66-6D21B65A3A4D Q37143869-19372EB5-B73C-4323-A607-D955331C5578 Q37157989-7D9128DD-E3AB-47CA-BD11-22D882C421C9 Q37766483-A01C528D-F090-4F30-AC7F-FA6795F6172D Q37778691-7DBF8D2A-536F-445F-BE8D-3DC5C21F7CDD Q37809156-683683D6-8FE1-40A1-94B9-E0988A740C3E Q38558703-2AE96BA6-0739-4CBE-8FF9-5CCE083BF8F6 Q38584979-5D38F1A8-F3D3-4C0F-8396-81A249F27BF2 Q39637191-AEAF9E32-2FC3-45B7-9D39-940A40301160 Q39828440-C747F4D8-60F8-4911-A644-ABC79AD782BC Q42145973-95255FE9-DB22-43FA-9533-B53D52399698 Q43533166-58E87ABD-8238-4018-8BAB-21A7539D9836 Q43565856-8000BC13-1001-4013-820A-B96A74F1B3F1 Q46624489-6DAB96CA-FD24-4153-9C0F-FCF977B5AEB5 Q50894663-CBD09C4F-A011-480F-BC54-1D6765DFF6D1 Q53093196-B6F4FD18-5AC5-45AD-8C12-A454E15BCA99 Q56897916-C345EC97-0022-4B09-930F-1D2CBD8C8237 Q56897986-CEBDC3DA-E041-4FA4-9240-A012A979C756 Q56903073-41DFC915-65DB-4AE2-A0CD-952B7BEBA504

P2860

CTLA-4 regulates cell cycle progression during a primary immune response.

http://www.wikidata.org/entity/Q34520577

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

CTLA-4 regulates cell cycle progression during a primary immune response.

@ast

CTLA-4 regulates cell cycle progression during a primary immune response.

@en

CTLA-4 regulates cell cycle progression during a primary immune response.

@nl

type

label

CTLA-4 regulates cell cycle progression during a primary immune response.

@ast

CTLA-4 regulates cell cycle progression during a primary immune response.

@en

CTLA-4 regulates cell cycle progression during a primary immune response.

@nl

prefLabel

CTLA-4 regulates cell cycle progression during a primary immune response.

@ast

CTLA-4 regulates cell cycle progression during a primary immune response.

@en

CTLA-4 regulates cell cycle progression during a primary immune response.

@nl

P1433

Q34520577-585089E4-C1EF-4382-8A5A-476A9EFDBCA3

P1476

Q34520577-3CDE7DE7-A7D8-4318-852A-F40E11A55BCF

P2093

Q34520577-3EA2CF4D-9DF5-4A21-9772-2FA98BE41485

Q34520577-6464DA6B-AE1A-4D24-B713-8F49863C6369

Q34520577-8DD5E59E-4EB7-4997-854B-59539CA21231

Q34520577-BD2FCD5C-8D17-445D-A23A-84101FFE9158

Q34520577-DA4CC74E-F6EF-4A3A-86A7-91C9A29FE275

Q34520577-E3A04A92-F6A1-4CE6-8C7A-81BDED0C42A1

P2860

Q34520577-0D996A02-7358-4FCE-AAC4-F0BBA37E1813

Q34520577-0DE4B373-7554-44DF-8135-A68FF2490D10

Q34520577-13C87B2C-0AE8-4AA6-BF98-AD1CB28430D5

Q34520577-14734917-1112-4EDE-8DD7-D78784AC330E

Q34520577-1EAB7DAD-B225-441C-AD6A-F4798435D47C

Q34520577-4B2E2A52-D6EF-42D4-9444-C29686FFB560

Q34520577-4C487F59-5702-4D43-8CA3-9D8CCAB426FC

Q34520577-4CDFAE7A-0948-4A9C-AD28-D73BE747EB44

Q34520577-4E2E93C7-E0A5-4E84-A5E4-33D487E2E306

Q34520577-5D17F2B2-999A-4305-9EAD-C1AA5E3D25A1

P304

Q34520577-B85013D8-23D3-46B1-9610-AC57321E7F69

P31

Q34520577-3BF33ADB-DD79-49BA-A402-A1CACD6AE589

P356

Q34520577-6A2A0AC1-F867-46C4-9CF9-A479E8C640B1

P407

Q34520577-AEDD5CCC-59B6-49CD-A28C-8FCAC07FBF86

P433

Q34520577-DCA77F2D-E65B-42B1-9C85-1BBED89D635A

P478

Q34520577-189C3F6C-531E-4166-8D81-543110A791F7

P50

Q34520577-C8863B03-B85F-4B82-AAB9-9ACB3C6DCC4D

P577

Q34520577-25628C65-FE8B-4551-BF73-B0282F30F9EB

P698

Q34520577-BDA53E7E-F929-4EA4-B7EA-4DD6F126E629

P356

1521-4141(200202)32:2%3C366::AID-IMMU366%3E3.0.CO;2-5

P1433

European Journal of Immunology

P1476

CTLA-4 regulates cell cycle progression during a primary immune response

@en

P2093

Anup Kubal

http://www.w3.org/2001/XMLSchema#string

Arlene H Sharpe

http://www.w3.org/2001/XMLSchema#string

Didier A Mandelbrot

http://www.w3.org/2001/XMLSchema#string

Mariette A Oosterwegel

http://www.w3.org/2001/XMLSchema#string

Rebecca J Greenwald

http://www.w3.org/2001/XMLSchema#string

Vassiliki A Boussiotis

http://www.w3.org/2001/XMLSchema#string

P2860

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

CTLA-4 ligation blocks CD28-dependent T cell activation

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein

Inhibitors of mammalian G1 cyclin-dependent kinases

D-type cyclin-dependent kinase activity in mammalian cells

P304

366-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Diane van der Woude

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11807776

http://www.w3.org/2001/XMLSchema#string